Drug repurposing in oncology - Authors' reply

Affiliations

¹ School of Medicine and Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
² Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94158, USA. Electronic address: vinayak.prasad@ucsf.edu.

Comment

Audrey A Tran et al. Lancet Oncol. 2020 Dec.

. 2020 Dec;21(12):e544.

doi: 10.1016/S1470-2045(20)30692-6.

¹ School of Medicine and Division of Hematology Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
² Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94158, USA. Electronic address: vinayak.prasad@ucsf.edu.

No abstract available

Comment on

Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy.
Tran AA, Prasad V. Tran AA, et al. Lancet Oncol. 2020 Sep;21(9):1134-1136. doi: 10.1016/S1470-2045(20)30424-1. Lancet Oncol. 2020. PMID: 32888447 No abstract available.
Drug repurposing in oncology.
Bouche G, Gedye C, Meheus L, Pantziarka P. Bouche G, et al. Lancet Oncol. 2020 Dec;21(12):e542. doi: 10.1016/S1470-2045(20)30561-1. Lancet Oncol. 2020. PMID: 33271099 No abstract available.
Drug repurposing in oncology.
Frantzi M, Latosinska A, Mokou M, Mischak H, Vlahou A. Frantzi M, et al. Lancet Oncol. 2020 Dec;21(12):e543. doi: 10.1016/S1470-2045(20)30610-0. Lancet Oncol. 2020. PMID: 33271100 No abstract available.